Skip to content
value.today

Odyssey Therapeutics, Inc.

🇺🇸 Medfield, Massachusetts, USABiotechnologyFounded 2021
Total raised
$499 M
3 rounds on record
Latest round
$214 M
Jun 2025
First round on record
May 2022
Today
Went public
See the company page

Odyssey Therapeutics, Inc. is listed today as Odyssey Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Odyssey Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2025$214 MNo. 3$50 to $250 million

Odyssey Therapeutics, Inc.: Raise no. 3, Jun 2025

Investors in this round

55 investors had bought by the notice of Dec 4, 2025: 55 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Odyssey Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$214 M of $214 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gary D. Glick · Executive Officer, Director
  • Jason F. Haas · Executive Officer · CFO
  • Carl D. Gordon · Director
  • Carolyn F. Ng · Director
  • Jeffrey D. Leiden · Director
  • Jill D. Carroll · Director
  • Ksenija F. Pavletic · Director
  • Nan D. Li · Director
  • Nia F. Tatsis · Director
  • Paulina D. Hill · Director
  • Shelley F. Chu · Director
  • Timothy D. Walbert · Director
  • Valerie D. Odegard · Director
  • lan F. Smith · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gary D. Glick, President & CEO. Source: SEC Form D, newest notice filed Dec 4, 2025. Read the notice at the SEC.

equity, optionsSEC
Oct 2023$117 MNo. 2$50 to $250 million

Odyssey Therapeutics, Inc.: Raise no. 2, Oct 2023

Investors in this round

43 investors had bought by the notice of Aug 14, 2024: 43 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Odyssey Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$117 M of $121 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gary D. Glick · Executive Officer, Director
  • Carl D. Gordon · Director
  • Charles M. Baum · Director
  • Ian M. Smith · Director
  • Jeffrey M. Leiden · Director
  • Jill D. Carroll · Director
  • Lorence M. Kim · Director
  • Timothy M. Walbert · Director
  • Valerie D. Odegard · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gary D. Glick, President & CEO. Source: SEC Form D and 1 amendment, newest notice filed Aug 14, 2024. Read the notice at the SEC.

equitySEC
May 2022$168 MNo. 1$50 to $250 million

Odyssey Therapeutics, Inc.: Raise no. 1, May 2022

Investors in this round

34 investors had bought by the notice of Oct 27, 2022: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Odyssey Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$168 M of $175 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gary D Glick · Executive Officer, Director
  • Carl D Gordon · Director
  • Charles D Baum · Director
  • Jeffrey D Leiden · Director
  • Jill D Carroll · Director
  • Valerie D Odegard · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gary D. Glick, President & CEO. Source: SEC Form D, newest notice filed Oct 27, 2022. Read the notice at the SEC.

equitySEC
Aug 2021$92 MIssued in a merger or acquisition$50 to $250 million

Odyssey Therapeutics, Inc.: Private sale, Aug 2021

Investors in this round

63 investors had bought by the notice of Oct 14, 2021: 63 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Odyssey Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$92 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gary D Glick · Executive Officer, Director
  • Carl D Gordon · Director
  • Chuck D Baum · Director
  • Jill D Carroll · Director
  • Valerie D Odegard · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gary D. Glick, President & CEO. Source: SEC Form D, newest notice filed Oct 14, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Odyssey Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2025).

    SEC Form D · Dec 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2025

That is all the official record says: Odyssey Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Odyssey Therapeutics, Inc. are on record.

Investors#

5 named in official filings. Open an investor to see everything it has backed.

Investors in Odyssey Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Anthony W. OpipariPersonnot statednot statedHeld Series A, B, C and D preferred stock (Form 3, 2026)SEC Form 3
Dimension Capital II, L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, director (Form 3, 2026)SEC Form 3
Gary D. GlickPersonnot statednot statedHeld Series C and D preferred stock, director (Form 3, 2026)SEC Form 3
SR One Capital Management, LLCFund or asset managernot statednot statedHeld Series A, A-2, B, C and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Tpg Gp A, LLCFund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2026)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 55 investors.

Largest shareholders today

Institutions holding Odyssey Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Odyssey Therapeutics, Inc.
NameRoleNamed in
Gary D. GlickExecutive officerDec 2025
Jason F. HaasCFODec 2025
Gary D GlickExecutive officerOct 2022
Carl D. GordonDirectorDec 2025
Carolyn F. NgDirectorDec 2025
Gary D. GlickDirectorDec 2025
Jeffrey D. LeidenDirectorDec 2025
Jill D. CarrollDirectorDec 2025
Ksenija F. PavleticDirectorDec 2025
Nan D. LiDirectorDec 2025
Nia F. TatsisDirectorDec 2025
Paulina D. HillDirectorDec 2025
Shelley F. ChuDirectorDec 2025
Timothy D. WalbertDirectorDec 2025
Valerie D. OdegardDirectorDec 2025
lan F. SmithDirectorDec 2025
Charles M. BaumDirectorAug 2024
Ian M. SmithDirectorAug 2024
Jeffrey M. LeidenDirectorAug 2024
Lorence M. KimDirectorAug 2024
Timothy M. WalbertDirectorAug 2024
Jeffrey Charles LeidenDirectorDec 2023
Lorence Charles KimDirectorDec 2023
M. Charles BaumDirectorDec 2023
Carl D GordonDirectorOct 2022
Charles D BaumDirectorOct 2022
Gary D GlickDirectorOct 2022
Jeffrey D LeidenDirectorOct 2022
Jill D CarrollDirectorOct 2022
Valerie D OdegardDirectorOct 2022
Chuck D BaumDirectorOct 2021

Went public since 2026. Its SEC number is that of a company listed on a stock exchange.